Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Biohaven Ltd. ( (BHVN) ).
On January 6, 2026, Biohaven Ltd. agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at $10.00 per share in a block transaction under its existing at-the-market equity program. The deal is expected to provide Biohaven with $125 million in gross proceeds before expenses, bolstering its capital position through a sizable, targeted equity raise that underscores ongoing investor appetite for the company’s stock and supports its ability to fund operations and pipeline development.
The most recent analyst rating on (BHVN) stock is a Hold with a $11.50 price target. To see the full list of analyst forecasts on Biohaven Ltd. stock, see the BHVN Stock Forecast page.
Spark’s Take on BHVN Stock
According to Spark, TipRanks’ AI Analyst, BHVN is a Neutral.
The score is primarily held down by weak financial performance—no revenue, large losses, heavy cash burn, and increased balance-sheet risk from negative equity and higher debt. Technicals are only modestly supportive in the near term while the longer-term trend remains bearish, and valuation is difficult to support given negative earnings. The recent $200M financing is a partial offset by improving liquidity.
To see Spark’s full report on BHVN stock, click here.
More about Biohaven Ltd.
Biohaven Ltd. is a biopharmaceutical company that develops and commercializes therapies, with its common shares listed and available for sale through public equity offering programs in the U.S. capital markets.
Average Trading Volume: 3,980,287
Technical Sentiment Signal: Sell
Current Market Cap: $1.32B
See more insights into BHVN stock on TipRanks’ Stock Analysis page.